LabStyle President and CEO Erez Raphael to Present and Demonstrate Dario™ at the Biotech Showcase 2014 in San Francisco, January 13, 2014 at 8:30 a.m.

“I am very much looking forward to presenting at the Biotech Showcase and to meeting everyone.  During my presentation, I plan to review our progress to date, our current status and our plans for the coming year,” said Mr. Raphael.  “We believe that the right mobile health platform for diabetes and blood glucose monitoring can transform the quality of diabetes care.   I will explain why Dario^™ is a game changer and demonstrate how it will empower people with diabetes to take charge of their health with the right tools, insights, and support, right in their pocket.”

The audio portion of Mr. Raphael’s presentation will be available live at the following link.  A playback of the audio portion of the presentation will be available for thirty days following at the same link.  The slide presentation will be available at this link.

The complete Dario^™ diabetes management platform combines an all-in-one, blood glucose monitoring system, a smart phone application (iOS & Android), and a website application.

LabStyle’s world roll-out of the Dario^™ diabetes management platform began on December 12^th with the market launch of the Dario^™ iOS app in the United Kingdom, Australia and New Zealand. The Dario^™ iOS app is now available in these countries for free download at the Apple app store. LabStyle remains on course to launch the Dario^™ iOS app in Italy and Belgium and the Dario^™ Android app, in the United Kingdom, New Zealand, Australia, Italy and Belgium – both during first quarter 2014.  Plans are also on track to soft launch the Dario^™ all-in-one blood glucose monitoring system in the United Kingdom and in Italy during first quarter 2014. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario^™Blood Glucose Monitoring System at the close of 2013.

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB:DRIO) is a mobile health (mHealth) company developing and commercializing patent-pending technology providing consumers with laboratory-testing capabilities using smart phones.  LabStyle’s flagship product, Dario™, is a mobile, cloud-based, diabetes management platform which includes an ‘all-in-one’, pocket-sized, blood glucose monitoring system, iOS and Android apps and a web application.  Dario™ received CE mark certification in September 2013 and began its world rollout in select countries in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services.  For more information: www.mydario.com and http://mydario.investorroom.com.

Cautionary Note Regarding Forward-Looking Statements

This news release, the presentation referred to herein and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of FDA review of Dario^™, the Company’s anticipations of the functionality of Dario^™, and the results of the Company’s commercialization efforts for Dario^™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Dario™ and the Dario™ logo are trademarks owned by LabStyle Innovation Ltd.

© 2013 LabStyle Innovations Corp.  All rights reserved.